A team of Canadian and French researchers have shown for the first time that miniature antibodies, called nanobodies, can get ...

By fusing enzyme fragments to antibodies, researchers from Institute of Science Tokyo, Japan, developed an innovative enzyme ...

Researchers have uncovered and then overcome an obstacle that has led to the failure of pioneering efforts in ...

Doctors at New York University say two new studies show that they are a significant step closer to making cross-species kidney transplants a real option in the near future.

Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079), an anti-CD38 monoclonal antibody with ...

By fusing enzyme fragments to antibodies, researchers from the Institute of Science Tokyo, in Japan, developed an innovative enzyme switch called "Switchbody," which is activated when bound to its ...

3D printing technology enables precise drug design, personalized dosing, and versatile release modes, benefiting patient-centric treatments. At AAPS PharmSci 360, Xialing Li, PhD, says 3D-printed ...

Being born with two X chromosomes brings a host of health benefits, and recognising this could lead to personalised medical ...

Takeda presents new data showing mezagitamab sustained effect on kidney function 18 months after treatment in primary IgA nephropathy: Osaka, Japan Monday, November 10, 2025, 15:0 ...

Takeda Pharmaceutical Co. Ltd.’s anti-CD38 antibody, mezagitamab (TAK-079), sustained kidney function up to 18 months after ...

A new approach targets the B-cell pathway with bispecific antibodies, building on decades of research that establishes the ...